Search clinical trials for: Intravenous Rituximab

Total 9470 results

University of Washington
Bayer

Terminated

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Lymphoid Leukemia

United States
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

MALT Lymphoma

Switzerland, Italy, France
Asklepion Pharmaceuticals, LLC

Completed

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol

Atrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal Defect

United States
Eli Lilly and Company

Completed

A Study of LY3016859 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Wake Forest University Health Sciences

Completed

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

Multiple Sclerosis

United States
M.D. Anderson Cancer Center

Terminated

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

Leukemia | Metastatic Malignant Neoplasm to the Leptomeninges | Lymphoid Malignancies

United States
Hoffmann-La Roche

Completed

A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Non-Hodgkin's Lymphoma

Italy
Hoffmann-La Roche

Completed

An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)

Rheumatoid Arthritis

Finland
Hoffmann-La Roche

Completed

SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

Rheumatoid Arthritis

France
University of California, San Francisco
Genentech, Inc.

Completed

The Effect of Rituximab on the Development of Anti-Donor Antibodies

Renal Transplant Rejection

United States
Genentech, Inc.
Seagen Inc.

Completed

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Lymphoma | Leukemia | Lymphoproliferative Disorder

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Nagoya University
Japan Agency for Medical Research and Development; Zenyaku Kogyo Co., Ltd.

Completed

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies (RECIPE)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Japan
Hoffmann-La Roche

Completed

An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)

Lymphocytic Leukemia, Chronic

Spain
Sanofi

Completed

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Norway, Austria, France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia
Georg Hess, MD
Roche Pharma AG; Klinikum Frankfurt Höchst

Completed

Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma (Mz-135)

Relapsed Non-Hodgkin-Lymphoma
University of Vermont
Genentech, Inc.

Completed

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

Refractory Myasthenia Gravis

United States
Seoul National University Childrens Hospital

Unknown

Rituximab Trial for Pediatric Nephrotic Syndrome (RTX2012)

Steroid Resistant Nephrotic Syndrome | Steroid Dependent Nephrotic Syndrome

Korea, Republic of
National Institute of Neurological Disorders and...

Completed

Rituximab to Treat Stiff Person Syndrome

Stiff Person Syndrome

United States
University Medical Center Groningen
Hoffmann-La Roche

Completed

Rituximab Treatment in Sjogren's Syndrome

Sjogren's Syndrome

Netherlands
Chaitanya Hospital, Pune

Unknown

Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy (BMMNC)

Muscular Dystrophy | Duchenne Muscular Dystrophy

India
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
African Academy of Methodology and Statistics

Suspended

Rituximab in Patients With Acute Rheumatic Fever (AGRAF-2)

Rheumatic Heart Disease in Children

Senegal
Hansa Biopharma AB

Recruiting

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)

Kidney Transplantation in Highly Sensitized Patients

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Richter Syndrome | Refractory Transformed Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Lixia Sheng

Recruiting

Clinical Study of OR for Second-line Treatment of Refractory MZL

OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma

China
Shoichi Maruyama MD PhD

Recruiting

Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome (PRIME)

Glomerulonephritis, Membranous | Nephrotic Syndrome，Idiopathic

Japan
CHU de Reims

Unknown

Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions (RADIO-LYMPH)

Indolent Cutaneous B Cell Lymphomas

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
Oslo University Hospital
Norwegian Cancer Society; Helse Sor-Ost

Completed

Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma (Lymvac-1)

Follicular Lymphoma

Norway
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Karolinska University Hospital

Completed

Safety and Efficacy Study of Rituximab in Renal Transplantation

Renal Transplantation

Sweden
Lymphoma Study Association

Completed

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Lymphoma

France, Belgium
Shandong University
China Medical University, China; The Affiliated Hospital of the Chinese Academy... and other collaborators

Withdrawn

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
University College, London

Completed

The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United Kingdom
University Hospital, Geneva

Active, not recruiting

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma (FRILLY)

Aggressive B-Cell Non-Hodgkin Lymphoma

Switzerland
Jean M. Tersak, M.D.
Genentech, Inc.

Terminated

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Neuroblastoma | Opsoclonus-myoclonus
Institut fuer anwendungsorientierte Forschung und...
German High-Grade Non-Hodgkin's Lymphoma Study Group; University Hospital Goettingen

Completed

Allo-hNHL (FluBuCy)

Non-Hodgkin's Lymphoma

Germany
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Pharmacokinetics, Efficacy and Safety of the 304 Injection

CD20 Positive B Cell NHL

China
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

Rheumatoid Arthritis

Sweden, Canada
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

Italy
Stanford University
Genentech and Biogen IDEC

Completed

Rituximab for Pediatric Renal Transplant Rejection

Kidney Transplantation

United States
GlaxoSmithKline

Completed

SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS

Lung Injury, Acute

United States
International Extranodal Lymphoma Study Group (IELSG)

Completed

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Lymphoma, Mucosa-Associated Lymphoid Tissue

United Kingdom, France, Italy, Switzerland, Spain, Belgium
Assistance Publique - Hôpitaux de Paris
Hoffmann-La Roche

Completed

Rituximab in Auto-Immune Hemolytic Anemia (RAHIA)

Warm Autoimmune Hemolytic Anemia

France
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China

Search clinical trials for: Intravenous Rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations